Metabolic syndrome increases the risk of aggressive prostate cancer detection

Juan Morote, Jordi Ropero, Jacques Planas, Juan M. Bastarós, Gueisy Delgado, José Placer, Anna Celma, Inés M. De Torres, Joan Carles, Jaume Reventós, Andreas Doll

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

47 Citas (Scopus)

Resumen

Objective To further examine the association between metabolic syndrome (MS), prostate cancer (PC) detection risk and tumour aggressiveness. Patients and Methods From 2006 to 2010, 2408 men not receiving 5α-reductase inhibitors were scheduled for prostatic biopsy due to PSA above 4 ng/mL and/or abnormal digital rectal examination. MS was evaluated according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition. Tumour aggressiveness was evaluated through biopsy Gleason score, clinical stage and risk of biochemical recurrence after primary treatment. Results The rates of PC detection were 34.5% and 36.4% respectively in men with and without MS, P = 0.185. High grade PC rates (Gleason score 8-10) were 35.9% and 23.9% respectively, P < 0.001. The advanced disease rates (cT3-4 N0-1 M0-1) were 17% and 12.7% respectively, P = 0.841. The high risk PC rates (cT2c-4 or Gleason score 8-10 or PSA > 20) were 38.5% and 33.0% respectively, P = 0.581. Multivariate analysis confirmed that MS was not associated with the risk of PC detection but it was associated with an increased risk of high grade tumours (odds ratio 1.75, 95% CI 1.26-2.41), P < 0.001. Conclusion MS seems not be associated with an increased risk of PC detection but it is associated with an increased risk of more aggressive tumours. © 2012 BJU International.
Idioma originalInglés
Páginas (desde-hasta)1031-1036
PublicaciónBJU International
Volumen111
N.º7
DOI
EstadoPublicada - 1 jun 2013

Huella

Profundice en los temas de investigación de 'Metabolic syndrome increases the risk of aggressive prostate cancer detection'. En conjunto forman una huella única.

Citar esto